Urveesh Sharma
This is a likely match — the affiliation was inferred from OpenAlex, ORCID, and web sources but has not been fully confirmed. Treat with appropriate caution.
Role not yet determined Is this you? Add your title
Research Areas
Links
Biography and Research Information
OverviewAI-generated summary
Urveesh Sharma's research focuses on comparative outcomes and treatment efficacy across various medical conditions, utilizing real-world data. Recent publications investigate the comparative effectiveness of different medications for B-cell malignancies, comparing ibrutinib with acalabrutinib and zanubrutinib regarding mortality and toxicity. Other work examines vedolizumab versus infliximab for immune checkpoint inhibitor-induced colitis, analyzing associations with hospitalization, flares, disease progression, steroid use, and surgical outcomes. Sharma also studies healthcare disparities in achalasia treatment, comparing laparoscopic Heller myotomy with peroral endoscopic myotomy (POEM), and reviews clinical reflux after POEM in salvage versus naive patients. Additional research includes real-world outcomes of upadacitnib compared to other agents for ulcerative colitis and the potential protective mechanism of GLP-1 receptor agonists against post-ERCP pancreatitis.
Metrics
- Publications: 15
Selected Publications
-
POSTER: CLL-1382: Comparing Ibrutinib With Acalabrutinib and Zanubrutinib in B-Cell Malignancies: A Real-World Study of Mortality and Toxicity (2026)
-
CLL-1382: Comparing Ibrutinib With Acalabrutinib and Zanubrutinib in B-Cell Malignancies: A Real-World Study of Mortality and Toxicity (2026)
Collaboration Network
Top Collaborators
- CLL-1382: Comparing Ibrutinib With Acalabrutinib and Zanubrutinib in B-Cell Malignancies: A Real-World Study of Mortality and Toxicity
- POSTER: CLL-1382: Comparing Ibrutinib With Acalabrutinib and Zanubrutinib in B-Cell Malignancies: A Real-World Study of Mortality and Toxicity
- CLL-1382: Comparing Ibrutinib With Acalabrutinib and Zanubrutinib in B-Cell Malignancies: A Real-World Study of Mortality and Toxicity
- POSTER: CLL-1382: Comparing Ibrutinib With Acalabrutinib and Zanubrutinib in B-Cell Malignancies: A Real-World Study of Mortality and Toxicity
- CLL-1382: Comparing Ibrutinib With Acalabrutinib and Zanubrutinib in B-Cell Malignancies: A Real-World Study of Mortality and Toxicity
- POSTER: CLL-1382: Comparing Ibrutinib With Acalabrutinib and Zanubrutinib in B-Cell Malignancies: A Real-World Study of Mortality and Toxicity
- CLL-1382: Comparing Ibrutinib With Acalabrutinib and Zanubrutinib in B-Cell Malignancies: A Real-World Study of Mortality and Toxicity
- POSTER: CLL-1382: Comparing Ibrutinib With Acalabrutinib and Zanubrutinib in B-Cell Malignancies: A Real-World Study of Mortality and Toxicity
- CLL-1382: Comparing Ibrutinib With Acalabrutinib and Zanubrutinib in B-Cell Malignancies: A Real-World Study of Mortality and Toxicity
- POSTER: CLL-1382: Comparing Ibrutinib With Acalabrutinib and Zanubrutinib in B-Cell Malignancies: A Real-World Study of Mortality and Toxicity
- CLL-1382: Comparing Ibrutinib With Acalabrutinib and Zanubrutinib in B-Cell Malignancies: A Real-World Study of Mortality and Toxicity
- POSTER: CLL-1382: Comparing Ibrutinib With Acalabrutinib and Zanubrutinib in B-Cell Malignancies: A Real-World Study of Mortality and Toxicity
Similar Researchers
Based on overlapping research topics